Reuters -- AstraZeneca (AZN.L) and Abbott Laboratories (ABT.N) have filed for U.S. regulatory approval of a new two-in-one cholesterol drug called Certriad that they hope will become a major seller.
Reuters -- AstraZeneca (AZN.L) and Abbott Laboratories (ABT.N) have filed for U.S. regulatory approval of a new two-in-one cholesterol drug called Certriad that they hope will become a major seller.
